

General Information

Name: Prof Dr. med. Lars Bullinger
Date of Birth: 20.09.1971
Gender: Male
Address: Department of Hematology, Oncology and Tumorimmunology,
Charité University Medicine
Augustenburger Platz 1, 13353 Berlin, Germany
Phone: +49 30 450 553192
Fax: +49 30 450 553987
E-Mail: lars.bullinger@charite.de
Current Position: Medical Director, Department of Hematology, Oncology and
Tumorimmunology

Academic Education

1999 Medical Licensing Examination, Heidelberg University
1998 Baylor College of Medicine, TX; Duke University, NC
1992-1998 Medical School, Heidelberg University

Academic Degrees

2017 Full Professor in Hematology and Oncology (Charité)
2011 Assistant Professor (apl. Professor) in Personalized Medicine
(Ulm University)
2008 Postdoctoral Thesis (*Habilitation*) in Internal Medicine (Ulm University)
2000 Doctoral Thesis (*Dr. med.*) (Heidelberg University)

Professional Experience

Since 2017 Director, Department of Hematology, Oncology and Tumor-
immunology (CVK), Charité University Medicine, Berlin
2016-2017 Professor for Personalized Medicine (W3), Ulm University, Germany
2016-2017 Executive Deputy Director, Center of Internal Medicine,
Ulm University, Germany
2013-2017 Head of the Oncology Section, Department of Internal Medicine III
(Prof. H. Döhner), Ulm University
2011-2017 Attending Physician, Department of Internal Medicine III (Prof. H.
Döhner), Ulm University
2010 Sabbatical in the Department of Pediatric Oncology (Prof. S. A.
Armstrong), Dana Farber Cancer Institute, Boston, USA
2004-2009 Residency/Fellowship, Department of Internal Medicine III (Prof. H.
Döhner), Ulm University
2002-2003 Postdoctoral fellowship in the Department of Pathology (Prof. J. D.
Pollack), Stanford University, USA (DFG scholarship)
1999-2001 Residency, Department of Internal Medicine III (Prof. H. Döhner), Ulm
University

Miscellaneous

Awards and Honors:

2015 Heisenberg Professor (DFG)
2011-2014 Heisenberg Scholarship (DFG)
2005 Franziska Kolb Award for Leukemia Research
2002-2003 DFG research scholarship
1998 DAAD scholarship

Publications

1. Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rücker FG, Lux S, Blätte TJ, Skambraks S, Krönke J, Heidel FH, Schnöder TM, Corbacioglu A, Gaidzik VI, Paschka P, Teleanu V, Göhring G, Thol F, Heuser M, Ganser A, Weber D, Sträng E, Kestler HA, Döhner H, Bullinger L*, Döhner K*. Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. **Nat Commun**. 2019;10(1):2031. *Equal contribution
2. Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L*, Dombret H*. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. **Leukemia**. 2018;32(12):2546-57. *Equal contribution
3. Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A. BCAT1 restricts α KG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. **Nature**. 2017;551(7680):384-88.
4. Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, Radtke I, Chao JR, Walsh MP, Song G, Andersson AK, Dang J, Dong L, Liu Y, Huether R, Cai Z, Mulder H, Wu G, Edmonson M, Rusch M, Qu C, Li Y, Vadodaria B, Wang J, Hedlund E, Cao X, Yergeau D, Nakitandwe J, Pounds SB, Shurtleff S, Fulton RS, Fulton LL, Easton J, Parganas E, Pui CH, Rubnitz JE, Ding L, Mardis ER, Wilson RK, Gruber TA, Mullighan CG, Schlenk RF, Paschka P, Döhner K, Döhner H, Bullinger L*, Zhang J,* Klco JM,* Downing JR.* The genomic landscape of core-binding factor acute myeloid leukemias. **Nat Genet**. 2016;48(12):1551-56. *Equal contribution
5. Krönke J, Fink EC, Hollenbach PW, MacBeth K, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Wah Man H, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Järås M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R, Ebert BL. Lenalidomide induces ubiquitination and degradation of casein kinase 1A1 in del(5q) MDS. **Nature**. 2015;523(7559):183-8.
6. Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MWM, Paschka P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K, Bullinger L. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin-remodeling and splicing. **Blood**. 2012;120(18):e83-92.
7. Gaidzik V, Paschka P, Späth D, Habdank M, Köhne C, Germing U, von Lilienfeld-Toal M, Held G, Horst HA, Haase D, Bentz M, Götze K, Döhner H, Schlenk RF, Bullinger L*, Döhner K*. TET2 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis of the AML Study Group (AMLSG). **J Clin Oncol**. 2012;30(12):1350-7. *Equal contribution
8. Bullinger L, Krönke J, Schön C, Radtke I, Urlbauer K, Botzenhardt U, Gaidzik V, Carió A, Senger C, Schlenk RF, Downing JR, Holzmann K, Döhner K, Döhner H. **Identification of Acquired Copy Number Alterations and Uniparental Disomies in Cytogenetically Normal Acute Myeloid Leukemia Using High-Resolution Single Nucleotide Polymorphism Analysis**. **Leukemia**. 2010;24(2):438-49.
9. Rucker FG*, Bullinger L*, Schwaenen C, Lipka DB, Wessendorf S, Frohling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. **J Clin Oncol**. 2006;24(24):3887-89. *Equal contribution
10. Bullinger L, Döhner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, Döhner H, Pollack JR. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. **N Engl J Med**. 2004;350(16):1605-16.